ABC has been very pleased with the ratings for the Kiefer Sutherland vehicle Designated Survivor, ordering a full 22 episode season not long after it debuted. While ratings have dipped a bit since, they still remain strong, and there's no reason to think the show will not be renewed. With 22 episodes ordered, there's little reason to justify the stock's current price of $19.61, as it should adjust to $22 on May 31, 2017, a 12.2% increase in 5.5 months, approximately 25% annually.
Designated Survivor could suddenly tank in the ratings, but there's almost nothing to suggest that DESURV won't adjust to $22 at the end of May.
Recommendation: If you have a small portfolio and need to invest in big, quick gains, DESURV isn't the stock for you. But if you have plenty of investible funds and need somewhere to invest, DESURV offers a nice pickup for you.
Monday, December 12, 2016
Jemaine Clement - HSX Pick of the Day for December 12, 2016
Jemaine Clement, star of Flight of the Conchords, provides the voice of Tamatoa in Walt Disney's Moana, a film that has topped the box office in each of its first three weeks of release, earning $144.7 million through Sunday, December 11th. Assuming a very conservative $10 million in gross in its fourth week, the film would adjust to $155 million. Moana will replace What We Do In The Shadows in Jemaine Clement's TAG, a film that grossed just $3,276,317. As a result, JCLEM will adjust up by a minimum of $30.34, putting his price at $42.11, up from his current price of $26.59.
Even if Moana were to somehow make no additional money over its current $144.7 million, JCLEM would still adjust to $40.05, a big profit over his current value.
Recommendation: Buy JCLEM long. After MOANA adjusts on December 20th, you would be wise to dump your stock in JCLEM. While his next film to drop from TAG range, Misery Loves Comedy, grossed just $5,260, it looks to be awhile until Clement appears in his next film, which will likely cause the stock to drop until the release date of his next effort approaches.
Even if Moana were to somehow make no additional money over its current $144.7 million, JCLEM would still adjust to $40.05, a big profit over his current value.
Recommendation: Buy JCLEM long. After MOANA adjusts on December 20th, you would be wise to dump your stock in JCLEM. While his next film to drop from TAG range, Misery Loves Comedy, grossed just $5,260, it looks to be awhile until Clement appears in his next film, which will likely cause the stock to drop until the release date of his next effort approaches.
Thursday, December 17, 2015
Julie Walters - HSX Pick of the Day for December 17, 2015
It's been more than four years since the final film in the Harry Potter franchise was released, but for the savvy investor, Harry and his friends still offer great opportunities for easy and guaranteed money on the HSX market.
Julie Walters (JWALT) appeared as Molly Weasley in the Harry Potter Series, and since the release of the last film has popped up in just four additional credits, most recently this year's Brooklyn. Brooklyn will de-list for somewhere between $15 and $18 million on December 22nd, and will enter JWALT's TAG range and push Gnomeo and Juliet out of TAG range. Gnomes and Juliet grossed $99,908,609, so even if we assume that Brooklyn tops out at $18 million, that's a difference of $81,908,609, or $16.38 in TAG value, dropping her TAG from $132.67 to roughly $116.29. JWALT is currently trading at $130.84, offering a gain of $14.55 (11%) per share in just one week to anyone savvy enough to short stock in JWALT.
As if that wasn't attractive enough, more profits are almost certainly on the horizon. The next film to fall out of TAG range is the final Harry Potter film, which grossed more than $381 million. While the Hollywood Stock Exchange does not list her next film (she has been busy shooting Indian Summers), assuming that Ms. Walters appears on screen again, her next film will almost certainly drop the value of JWALT dramatically as Harry Potter is pushed out of TAG range. The worst case scenario for an investor is that her next film grosses north of $250 million, which would keep her stock at exactly it's post-December 22nd price. Even if her next film was enormously successful and grossed $150 million, that would cause a drop in value of $30 per share, a gain to short sellers of roughly 26%. It might take awhile to collect, but with such a significant potential gain, investing in JWALT is a no brainer.
One more note: JWALT's next film to fall out of TAG range after Harry Potter is Brave, which brought home more than $237 million for Disney. Short selling JWALT will almost certainly offer big money for a long time to come.
RECOMMENDATION: Short as many shares of JWALT as you can afford, and hold onto them for a long time.
Julie Walters (JWALT) appeared as Molly Weasley in the Harry Potter Series, and since the release of the last film has popped up in just four additional credits, most recently this year's Brooklyn. Brooklyn will de-list for somewhere between $15 and $18 million on December 22nd, and will enter JWALT's TAG range and push Gnomeo and Juliet out of TAG range. Gnomes and Juliet grossed $99,908,609, so even if we assume that Brooklyn tops out at $18 million, that's a difference of $81,908,609, or $16.38 in TAG value, dropping her TAG from $132.67 to roughly $116.29. JWALT is currently trading at $130.84, offering a gain of $14.55 (11%) per share in just one week to anyone savvy enough to short stock in JWALT.
As if that wasn't attractive enough, more profits are almost certainly on the horizon. The next film to fall out of TAG range is the final Harry Potter film, which grossed more than $381 million. While the Hollywood Stock Exchange does not list her next film (she has been busy shooting Indian Summers), assuming that Ms. Walters appears on screen again, her next film will almost certainly drop the value of JWALT dramatically as Harry Potter is pushed out of TAG range. The worst case scenario for an investor is that her next film grosses north of $250 million, which would keep her stock at exactly it's post-December 22nd price. Even if her next film was enormously successful and grossed $150 million, that would cause a drop in value of $30 per share, a gain to short sellers of roughly 26%. It might take awhile to collect, but with such a significant potential gain, investing in JWALT is a no brainer.
One more note: JWALT's next film to fall out of TAG range after Harry Potter is Brave, which brought home more than $237 million for Disney. Short selling JWALT will almost certainly offer big money for a long time to come.
RECOMMENDATION: Short as many shares of JWALT as you can afford, and hold onto them for a long time.
Monday, June 9, 2014
6/10/2014 Pick - Marion Cotillard
Marion Cotillard (MCOTI) offers a great Hollywood Stock Exchange short opportunity. Marion Cotillard will adjust today, and her TAG will gain Blood Ties and lose Midnight in Paris. Blood Ties has earned less than a million dollars, while Midnight in Paris earned $56.82 million, meaning her TAG will fall over $11.00 per share from a current value of $64.47 to around $54 million. It's too late to get in on this drop, as the stock is frozen, but there's still time to make HSX money by shorting Marion Cotillard.
In 8 weeks, Marion Cotillard will adjust again to account for The Immigrant, dropping Contagion in the process. The Immigrant currently has grossed at $1,421,859. Even if it were to gross $5 million, which is unlikely, Contagion grossed $75,638,743, meaning MCOTI would drop approximately $14 a share, to around $40, offering a gain of over $24.
If that's not enough for you and you're willing to hold onto MCOTI even longer, the next movie to drop from TAG range will be The Dark Knight Rises, which grossed almost $450 million. This offers zero risk, since even if Cotillard's next film were to become the highest grossing film in film history, the stock would maintain its post The Immigrant price due to TAG rules. Even if the film is successful, this could offer huge opportunities.
As soon as MCOTI is unfrozen, make sure to short sell as many shares of Marion Cotillard as you can afford. It can offer a good short-term or great long-term profit.
In 8 weeks, Marion Cotillard will adjust again to account for The Immigrant, dropping Contagion in the process. The Immigrant currently has grossed at $1,421,859. Even if it were to gross $5 million, which is unlikely, Contagion grossed $75,638,743, meaning MCOTI would drop approximately $14 a share, to around $40, offering a gain of over $24.
If that's not enough for you and you're willing to hold onto MCOTI even longer, the next movie to drop from TAG range will be The Dark Knight Rises, which grossed almost $450 million. This offers zero risk, since even if Cotillard's next film were to become the highest grossing film in film history, the stock would maintain its post The Immigrant price due to TAG rules. Even if the film is successful, this could offer huge opportunities.
As soon as MCOTI is unfrozen, make sure to short sell as many shares of Marion Cotillard as you can afford. It can offer a good short-term or great long-term profit.
Sunday, June 8, 2014
6/8/2014 Pick - Tye Sheridan (TSHER)
Tye Sheridan has only been in a few movies, and so far his stock price is due almost entirely to the grosses of Tree of Life and Mud. The two films together earned $34.89 million. His third film on the exchange, David Gordon Green's Joe, just adjusted, and its small gross raised Tye Sheridan's TAG to $11,630,875. His stock quickly fell, and is currently trading at $7.59. After his next film is released, which is set to be Scouts vs. Zombies on March 13, 2015, Tye Sheridan will adjust to a minimum of $8.72, a gain of $1.13 or 14.9%. For those just starting out, this isn't a big enough gain to justify locking up funds for nine months, but for those with plenty of cash to invest, Tye Sheridan offers a nice guaranteed gain and the potential for more. Scouts vs. Zombies currently trades at $36.97; if the market is correct, Tye Sheridan's stock would jump to $17.97, more than doubling in value. Tye Sheridan is a good buy for those with big portfolios and cash to invest.
Friday, October 19, 2012
10/19/2012 Picks
Chris Messina - CMESS
Chris Messina has had a full dance card lately, with six films released in 2012 and his work on HBO's The Newsroom. Busy actors are the best f or HSX investing, especially those who make both large and small films, creating big fluctuations in TAG value.
CMESS is currently trading at $2.04 over a TAG of $1,189,702. Next Tuesday (October 23rd), CMESS will adjust for Celeste and Jesse Forever, which grossed $3,077,622. This will knock Monogamy and its $20,202 out of TAG range, which will adjust CMESS to $1.80.
So why is CMESS a must-buy if the stock will drop from $2.04 to $1.80 next Tuesday? Yes, it is a loss of 24 cents (though this can be eliminated by placing a limit order), but CMESS will almost immediately take a big jump. The next film to enter TAG range for CMESS is Argo, which has already grossed $26,568,000, and the next film leaving TAG range is Like Crazy, which grossed $3,388,210. This means that CMESS will jump a guaranteed $4.64, pushing the stock to $6.44, more than three times the stock's current value.
This stock is even more attractive since Argo will likely gross quite a bit more money based on strong reviews and positive audience response. CMESS could easily climb somewhere in the range of $5-10 beyond the guaranteed $4.64, making this an easy gain that will pay off in less than a month.
Chris Messina has had a full dance card lately, with six films released in 2012 and his work on HBO's The Newsroom. Busy actors are the best f or HSX investing, especially those who make both large and small films, creating big fluctuations in TAG value.
CMESS is currently trading at $2.04 over a TAG of $1,189,702. Next Tuesday (October 23rd), CMESS will adjust for Celeste and Jesse Forever, which grossed $3,077,622. This will knock Monogamy and its $20,202 out of TAG range, which will adjust CMESS to $1.80.
So why is CMESS a must-buy if the stock will drop from $2.04 to $1.80 next Tuesday? Yes, it is a loss of 24 cents (though this can be eliminated by placing a limit order), but CMESS will almost immediately take a big jump. The next film to enter TAG range for CMESS is Argo, which has already grossed $26,568,000, and the next film leaving TAG range is Like Crazy, which grossed $3,388,210. This means that CMESS will jump a guaranteed $4.64, pushing the stock to $6.44, more than three times the stock's current value.
This stock is even more attractive since Argo will likely gross quite a bit more money based on strong reviews and positive audience response. CMESS could easily climb somewhere in the range of $5-10 beyond the guaranteed $4.64, making this an easy gain that will pay off in less than a month.
Thursday, October 4, 2012
Easy Money with TV Stocks
After a dismal run at NBC in recent years, the network was excited to announce that it is ordering additional episodes of three new shows: Go On, The New Normal, and Revolution. This is good news for fans of these shows, but also great news for savvy HSX traders.
HSX TVStocks allow investors to bet on how many episodes of a new show will air during the 2012-2013 TV season. The stocks will pay out $1 per episode after the last episode of the season has aired. If you bought the stocks of any of these shows at their IPO price, you will have made a nice profit. But these stocks are still trading at artificially low prices, offering a chance to get in late and still make money at almost no risk.
Please note that it is still possible that any of these three shows could experience a ratings collapse that could lead to these episodes not being aired. However, these shows are all doing well, and it is extremely unlikely that these episodes won't air. The tiny risk that the fortunes of these shows can change is far outweighed by the near guarantee of making money on these stocks.
Go On (GOONBC) is currently trading at $18.75. With 22 episodes ordered, this stock is $3.25 below its value, offering a 17.3% gain. 17.3% over approximately seven months is a solid gain, and well above what interest would pay on cash. If you have a small portal and are tight on cash, there are more profitable investment options available. If you have a large portal with an excess of cash, GOONBC is a great place to park some money for awhile.
Revolution (RVOLUT) offers less attractive margins than GOONBC, but is still worth buying for those with large portfolios. It is currently priced at $19.46 per share, $2.54 below its expected value. Once again, this stock probably isn't a good choice for small portfolios, but the payout is well above HSX interest levels.
The best margin available is for The New Normal (NWNRML), priced at $16.67, $5.33 below value. This translates to a gain of 32.0% over approximately seven months. This is a no-brainer for large portfolios, but is worth considering for medium-sized portfolios as well. Strong traders can make more than this in seven months, but for less active traders, it is well worth considering parking funds in NWNRML and collecting a tidy profit next spring.
Subscribe to:
Posts (Atom)